Tybost
NDC Package 61958-1402-1
Package Information
Tybost is the concomitant use of TYBOST with atazanavir or darunavir and the following drugs is contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].Alpha 1-adrenoreceptor antagonist: alfuzosinAntianginal: ranolazineAntiarrhythmic: dronedaroneAnticonvulsants: carbamazepine, phenobarbital, phenytoinAnti-gout: colchicineAntimycobacterial: rifampinAntineoplastics: irinotecanThese contraindications apply only to TYBOST coadministered with atazanavirAntipsychotics: lurasidone, pimozideErgot Derivatives: dihydroergotamine, ergotamine, methylergonovineHerbal Products: St. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-1402 and is authorized under FDA application NDA203094.
Identification & Billing
- RxCUI: 1551993 - cobicistat 150 MG Oral Tablet
- RxCUI: 1551999 - Tybost 150 MG Oral Tablet
- RxCUI: 1551999 - cobicistat 150 MG Oral Tablet [Tybost]
- RxCUI: 2719618 - cobicistat 90 MG Oral Tablet
- RxCUI: 2719620 - Tybost 90 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-1402 - Tybost
- 61958-1402-1 - 30 TABLET, FILM COATED in 1 BOTTLE
- 61958-1402 - Tybost
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-1402-1 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Tybost, labeled by Gilead Sciences, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Gilead Sciences, Inc. on June 20, 2025. The current certification is valid through September 25, 2025.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958140201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.